The stock of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) last traded at $0.66, down -1.50% from the previous session.
ADAP stock price is now -21.97% away from the 50-day moving average and -40.55% away from the 200-day moving average. The market capitalization of the company currently stands at $169.96M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $4, H.C. Wainwright recently initiated with Buy rating for Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP). On May 30, 2024, Scotiabank recently initiated its ‘Sector Outperform’ rating on the stock quoting a target price of $3.15, while ‘Bryan Garnier’ rates the stock as ‘Buy’
In other news, Piccina Cintia, Chief Commercial Officer sold 24,531 shares of the company’s stock on Jun 18 ’24. The stock was sold for $22,814 at an average price of $0.93. Upon completion of the transaction, the Chief Commercial Officer now directly owns 38,293 shares in the company, valued at $25273.38. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17 ’24, Chief Executive Officer Rawcliffe Adrian sold 30,080 shares of the business’s stock. A total of $20,244 was realized by selling the stock at an average price of $0.67. This leaves the insider owning 44,848 shares of the company worth $29599.68. A total of 11.49% of the company’s stock is owned by insiders.
During the past 12 months, Adaptimmune Therapeutics Plc ADR has had a low of $0.42 and a high of $2.05. As of last week, the company has a debt-to-equity ratio of 0.93, a current ratio of 3.85, and a quick ratio of 3.82. The fifty day moving average price for ADAP is $0.86028 and a two-hundred day moving average price translates $1.12148 for the stock.
The latest earnings results from Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was released for 2024-06-30. The net profit margin was -25.63% and return on equity was -53.54% for ADAP. The company reported revenue of $40.9 million for the quarter, compared to $7.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 458.83 percent.
